Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Group 1 - The article discusses Edgewise Therapeutics, Inc. (EWTX) and its ongoing development of EDG-7500 despite safety concerns related to atrial fibrillation (AF) [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2] - The service is available for a monthly fee of $49, with a discounted annual plan at $399, offering a 33.50% savings [1] Group 2 - The article does not contain any specific financial data or performance metrics related to Edgewise Therapeutics or its products [4] - There are no disclosed positions or plans to invest in the companies mentioned, indicating an unbiased perspective in the analysis [3]